NYSE:RCUSArcus Biosciences Stock Price, Forecast & News

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCUS stock has increased by 83.9% and is now trading at $31.20. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcus Biosciences.

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Arcus Biosciences.

Arcus Biosciences Inc (NYSE:RCUS) released its earnings results on Tuesday, May, 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.07. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2 million. Arcus Biosciences had a negative net margin of 631.95% and a negative return on equity of 55.90%. View Arcus Biosciences' earnings history.

7 brokers have issued 1-year price targets for Arcus Biosciences' stock. Their forecasts range from $21.00 to $48.00. On average, they expect Arcus Biosciences' share price to reach $35.38 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View analysts' price targets for Arcus Biosciences.

News articles about RCUS stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. View the latest news aboutArcus Biosciences.

Arcus Biosciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 331,600 shares, a decrease of 50.7% from the April 30th total of 672,900 shares. Based on an average daily trading volume, of 562,500 shares, the short-interest ratio is currently 0.6 days. Approximately 1.2% of the shares of the stock are sold short. View Arcus Biosciences' Current Options Chain.

Some companies that are related to Arcus Biosciences include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Emergent Biosolutions (EBS), Zai Lab (ZLAB), PPD (SDGR), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), Amarin (AMRN), VBI Vaccines (VBIV), Protalix Biotherapeutics (PLX), Vanda Pharmaceuticals (VNDA) and Aduro BioTech (ADRO).

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.05%), State Street Corp (1.40%), Franklin Resources Inc. (0.99%), Geode Capital Management LLC (0.96%), JPMorgan Chase & Co. (0.84%) and Invesco Ltd. (0.62%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View institutional ownership trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Two Sigma Investments LP, Morgan Stanley, GSA Capital Partners LLP, UBS Group AG, Deutsche Bank AG, and MML Investors Services LLC. View insider buying and selling activity for Arcus Biosciences.

RCUS stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., Balyasny Asset Management LLC, Federated Hermes Inc., Nuveen Asset Management LLC, Geode Capital Management LLC, DAFNA Capital Management LLC, and Trexquant Investment LP. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg, and Terry J Rosen. View insider buying and selling activity for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $31.20.

Arcus Biosciences has a market capitalization of $1.44 billion and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.

The official website for Arcus Biosciences is www.arcusbio.com.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]